Drawn from the second International Menopause Society workshop held in Pisa, Italy, these 33 contributions by leading experts in the field address knowledge current as of June 2001 relevant to the controversy over hormone replacement therapy's role as a cancer activator. After several papers describing the genetic processes underlying carcinogenesis, the discussion turns to HRT's relationship to specific cancers: breast, endometrial, colon, melanoma, and ovarian. The final section weighs the benefits and risks of newer forms of HRT. Genazzani (obstetrics and gynecology, U. of Pisa) is president of the International Menopause Society, under whose auspices this volume is published. Annotation c. Book News, Inc., Portland, OR (booknews.com)
The clinical benefits of hormone replacement therapy in women have to be carefully balanced against the possible risks, and a particular theoretical concern relates to risks associated with various forms of female oncology. Because of conflicting reports, gynecologists and oncologists especially need a single, authoritative resource of up-to-date information. Hormone Replacement Therapy and Cancer, published in association with the International Menopause Society, provides the very consensus statement that clinicians need in this difficult and complex area.
Many of the world's leading specialists have contributed important chapters that provide state-of-the-art knowledge about the effects of hormones on women and possible cancer risks. The introductory section deals with carcinogenesis, and the other main sections cover HRT and breast cancer, endometrial cancer, colon cancer, melanoma and epithelial ovarian cancer. The concluding chapters discuss the benefits and risks of sp ecific therapies. An authoritative clinical reference with extensive bibliographic references and index, Hormone Replacement Therapy and Cancer covers all aspects of HRT and cancer based on the research available up to June 2001.
Rohkem infot Taylor & Francis e-raamatute kohta